RHA Redensity Filler Improves Perioral Rhytids Up To 52 Weeks

The Resilient Hyaluronic Acid (RHA) filler significantly improved perioral rhytids for up to 52 weeks.
The Resilient Hyaluronic Acid (RHA) filler significantly improved perioral rhytids for up to 52 weeks.

A study published in the January 2022 issue of Dermatologic Surgery confirmed the efficacy of Teoxane’s Resilient Hylauronic Acid Redensity (RHAR) soft tissue filler for perioral rhytids, with 66% of treated subjects maintaining improvement at 52 weeks.

Related: Newsmakers: RHA Dermal Fillers

The randomized, blinded, multicenter clinical study by Hema Sundaram, MD, et al, aimed to demonstrate superiority of RHAR over no-treatment control for correction of moderate-to-severe dynamic perioral rhytides.

Two hundred two subjects with moderate-to-severe perioral rhytides (Grade 2 or 3) were enrolled at eight study sites (Six in the U.S. and two in Canada). They were randomized 3:1 to treatment group or control. The mean ages in the treatment group and control groups were 61.6 ± 7.2 years and 60.7 ± 7.6 years, respectively, and 27% had Fitzpatrick skin phototypes IV to VI.

Related: RHA 3 for Hand Rejuvenation, 12-Month Follow-up

The total volume of filler—including initial and touch-up treatments—to achieve optimal correction of perioral rhytides was 2.8 ± 2.0 mL.

Blinded evaluators assessed efficacy using the proprietary Perioral Rhytids Severity Rating Scale (PR-SRS) and the Global Aesthetic Improvement Scale. Subjects were asked to self-assess their results using the FACE-Q patient-reported outcome measure and satisfaction scales.

Related: Non-cross-linked HA Filler Improves Firmness and Elasticity in Perioral Region

The treatment group showed statistically significant superiority over the control group at Week 8 (80.7% vs 7.8% responder rate). Most patients (66%) were still responders at Week 52.

Blinded evaluators rated the degree of aesthetic improvement at Week 8 as significantly higher for the treatment group than for the control group (92.5% vs 8.3%) with improvement still visible in 80.9% of subjects at their last visit (week 52).

The proportion of subjects satisfied with treatment peaked at 91.8% at Week 4 and was 88.3% at Week 52.

There were no serious treatment-related AEs (TRAEs), unanticipated device-related events or late-onset TRAEs, nodular complications or vascular compromise events. All TRAEs were mild to moderate in severity, all resolved, and none was deemed clinically significant.

More in Injectables